,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,earningsQuarterlyGrowth,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,earningsGrowth,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Dr. Leonard S. Schleifer M.D., Ph.D.', 'age': 69, 'title': 'Co-Founder, Pres, CEO & Co-Chairman', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 7004069, 'exercisedValue': 0, 'unexercisedValue': 256815824}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
1,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Dr. George D. Yancopoulos M.D., Ph.D.', 'age': 62, 'title': 'Co-Founder, Pres, Chief Scientific Officer & Co-Chairman', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 6593696, 'exercisedValue': 0, 'unexercisedValue': 242710064}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
2,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Mr. Robert E. Landry Jr.', 'age': 58, 'title': 'Exec. VP of Fin. & CFO', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1839460, 'exercisedValue': 11097488, 'unexercisedValue': 25114408}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
3,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Dr. Andrew J. Murphy Ph.D.', 'age': 63, 'title': 'Exec. VP of Research', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 1622950, 'exercisedValue': 19388300, 'unexercisedValue': 83458888}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
4,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Mr. Daniel P. Van Plew', 'age': 49, 'title': 'Exec. VP and GM of Industrial Operations & Product Supply', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 1954399, 'exercisedValue': 45282380, 'unexercisedValue': 24788798}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
5,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Ms. Marion E. McCourt', 'age': 62, 'title': 'Exec. VP of Commercial', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1500262, 'exercisedValue': 4246309, 'unexercisedValue': 8790830}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
6,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Ms. Patrice  Gilooly', 'title': 'Sr. VP of Quality Assurance & Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
7,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Mr. Christopher R. Fenimore', 'age': 51, 'title': 'Sr. VP, Head of Accounting & Controller', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
8,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Mr. Gerald  Underwood', 'title': 'Sr. VP of Technical Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
9,777 Old Saw Mill River Road,Tarrytown,NY,10591-6707,United States,914 847 7000,https://www.regeneron.com,Biotechnology,Healthcare,"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",12256,"{'maxAge': 1, 'name': 'Mr. Bob  McCowan', 'title': 'Sr. VP of IT & Chief Information Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,9,10,10,1693526400,1672444800,86400,2,832.38,832.85,822.4,835.71,832.38,832.85,822.4,835.71,0.0,0.185684,21.639948,19.003,1032250,1032250,603935,423130,423130,810.57,824.15,800,800,89387483136,668.0,847.5,7.0546045,781.4718,763.94244,0.0,0.0,USD,81793343488,0.33928,101359050,106741000,1360156,1268810,1689292800,1692057600,0.0125,0.02542,0.89447,2.31,0.0149,225.944,3.644266,1672444800,1703980800,1688083200,0.136,4298999808,38.05,43.33,4.24,6.455,16.987,NMS,EQUITY,REGN,REGN,"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc.",670602600,America/New_York,EDT,-14400000,823.4,1050.0,665.0,903.9,895.0,2.0,buy,21,8927699968,84.256,4815099904,2702200064,4.526,5.451,12670799872,11.251,118.474,0.09548,0.19232,7020000000,2257374976,4738800128,0.138,0.105,0.53739,0.38002,0.34882,USD,1.748
